Shionogi traded at 3,393.00 this Friday February 6th, decreasing 35.00 or 1.02 percent since the previous trading session. Looking back, over the last four weeks, Shionogi lost 19.37 percent. Over the last 12 months, its price rose by 56.40 percent. Looking ahead, we forecast Shionogi to be priced at 3,046.09 by the end of this quarter and at 2,692.46 in one year, according to Trading Economics global macro models projections and analysts expectations.
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The Company is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The Company mainly provides its products and services in Japan, Europe and North America markets.